0.02
0.00%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About SpectraCure AB (publ)
Its shares trade on Nasdaq Stockholm under the ticker SPEC.ST. It has been listed since 1 July 2015. In the fiscal year to 31 December 2025, it reported revenue of SEK 868,000 and a net loss of SEK 56.1m. At that date it held total assets of SEK 104.5m and shareholders' equity of SEK 93.5m.
SpectraCure AB engages in the research, development, and provision of equipment for cancer treatments. The company is headquartered in Lund, Skane. The company went IPO on 2015-07-01. The firm specializes in cancer treatment technology. The firm develops photodynamic therapeutics based on photosensitive materials activated by laser. The firm's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 1 Jul 2015
- Employees
- 16
- Website
- spectracure.com ↗
Leadership
Pay as last reported
- Mr. Jorgen WennbergIndependent Chairman of the Board
- Dr. Johannes SwartlingChief Executive Officer, since 2025
- Mr. Henrik LjungChief Financial Officer
- Mr. Marcelo ThompsonChief Technology Officer
- Ms. Annika AnderssonPublic Relations Manager
- Mr. Johan GlindreHead of Clinical Affairs
- Mr. Johan IngemanssonHead of Business Development
- Dr. Masoud KhayyamiDirector, since 2025
- Prof. Stefan Andersson-EngelsIndependent Director
- Mr. Jesper FreijIndependent Director
- Mr. Tomas KramarIndependent Director
- Mr. Patrik RingblomIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- SpectraCure AB employs 16 full-time staff members in Lund.
- The company specializes in interstitial photodynamic therapy for solid tumors.
- IDOSE software platform controls laser light for cancer treatments.
Weaknesses
- The firm has only 16 employees for global operations.
- Interstitial PDT is limited to internal organ tumors.
- The company went public on 1 July 2015.
Opportunities
- Interstitial PDT treats prostate cancer in internal organs.
- Photodynamic therapeutics target pancreas cancer tumors effectively.
- Photosensitive materials activate via laser for head and neck cancer.
Threats
- Solid tumors in internal organs require precise laser guidance.
- Photosensitizer drugs must be administered with dose control systems.
- Interstitial photodynamic therapy is complex for clinical adoption.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.